Impel Pharmaceuticals (FRA:84P) EV-to-Revenue : 5.37 (As of Jun. 03, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Impel Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Impel Pharmaceuticals's enterprise value is €105.20 Mil. Impel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was €19.60 Mil. Therefore, Impel Pharmaceuticals's EV-to-Revenue for today is 5.37.

The historical rank and industry rank for Impel Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:84P' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.22 Med: 5.92 Max: 1696.34
Current: 5.48

During the past 4 years, the highest EV-to-Revenue of Impel Pharmaceuticals was 1696.34. The lowest was 1.22. And the median was 5.92.

FRA:84P's EV-to-Revenue is ranked better than
58.94% of 1035 companies
in the Biotechnology industry
Industry Median: 8.2 vs FRA:84P: 5.48

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-03), Impel Pharmaceuticals's stock price is €0.0405. Impel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was €0.83. Therefore, Impel Pharmaceuticals's PS Ratio for today is 0.05.

Impel Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Impel Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impel Pharmaceuticals EV-to-Revenue Chart

Impel Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

210.76

6.29

Impel Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-Revenue	Get a 7-Day Free Trial											10.48	6.29	3.32	3.53	5.95

Competitive Comparison of Impel Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Impel Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impel Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Impel Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Impel Pharmaceuticals's EV-to-Revenue falls into.

Impel Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Impel Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	105.201	/	19.595
	=	5.37

Impel Pharmaceuticals's current Enterprise Value is €105.20 Mil.
Impel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.60 Mil.

Impel Pharmaceuticals (FRA:84P) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Impel Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0405	/	0.825
	=	0.05

Impel Pharmaceuticals's share price for today is €0.0405.
Impel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.83.

Impel Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Impel Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Impel Pharmaceuticals (FRA:84P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impel Pharmaceuticals Inc (FRA:84P) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

IMPLQ:USA

Address

201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119

Website

https://www.impelpharma.com

Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Impel Pharmaceuticals (FRA:84P) Headlines

No Headlines